NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes

Enrolling By InvitationN/A

Sponsor: Franciscus Gasthuis

Conditions: Severe Asthma

Interventions: Tapering of inhaled corticosteroid (ICS) treatment

Countries: Netherlands

To evaluate the relationship between starting tezepelumab treatment followed by tapering of inhaled corticosteroid (ICS) and ICS dose, metabolic outcomes, asthma control and exacerbation rate in a real world setting

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥18
* Patient diagnosed with severe asthma according to the GINA guidelines
* Written informed consent (AVG).
* Eligibility and willingness to present during an asthma exacerbation at the Franciscus hospital.
* Patient has received/or has been planned for at least one dose of tezepelumab
* Sufficient understanding of the Dutch or English language

Exclusion Criteria:

* Other underlying inflammatory or auto-immune diseases that require OCS treatment, such as rheumatologic disease, IBD etc.
* Pregnancy, because of the possible altered immunological status.
* Participation in an interventional study that interferes with this study.

Locations (1)

Rotterdam, South Holland, Netherlands